FDA Extends Capricor's Deramiocel Review by Three Months — Capricor Therapeutics, Inc.

Event summary

FDA extends PDUFA target action date for Deramiocel from August 22, 2026, to November 22, 2026.
Extension follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication.
FDA classified the submission as a major amendment, citing significant unmet medical need in Duchenne muscular dystrophy (DMD).
Deramiocel holds Orphan Drug, RMAT, and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe.

The big picture

The extension of the PDUFA target action date reflects the FDA's thorough review process for cell therapies targeting rare diseases. Capricor's submission of additional data underscores the strategic importance of upper limb function preservation in DMD, a critical unmet need in the market. The outcome of this review will influence the competitive landscape for DMD treatments, particularly in the context of Capricor's ongoing legal disputes with key players in the space.

What we're watching

Regulatory Dynamics: How the FDA's review of additional data will impact the approval timeline for Deramiocel.
Clinical Development: Whether the refined proposed indication focused on upper limb function will meet FDA standards.
Market Positioning: The pace at which Capricor can commercialize Deramiocel if approved, given ongoing litigation with Nippon Shinyaku and NS Pharma.